Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Core One Labs Inc. C.COOL

Alternate Symbol(s):  CLABF

Healthcare Cannabis
Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. The Company, through its wholly owned subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics.


CSE:COOL - Post by User

Core One Labs Inc.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(18)
•••
Post by 5baggercallson Apr 26, 2021 2:34pm
158 Views
Post# 33067955

Further Validation & advancement for biosynthetic psilocybin

Further Validation & advancement for biosynthetic psilocybin

Core One partnering with UBC (University of British Columbia) to optimise their bio-synthetic process in producing psilocybin using bacteria as “biological factories”. This processes allows COOL CLABF to produce psilocybin at 1/100 to 1/1000 of the market cost for synthetic pharma grade psilocybin.


This research is a win for COOL as UBC’s research budget, which is 600 MILLION dollars annually, will go to help advance this technology. UBC is a top 3 university in Canada and ranked 27th globally in academic ranking.

https://financialpost.com/globe-newswire/repeat-core-one-labs-vocan-biotechnologies-enters-into-collaborative-research-agreement-with-ubc
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities